You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國同輻(01763.HK)附屬前列腺癌創新藥獲內地批准開展臨床
阿思達克 03-16 09:42
中國同輻(01763.HK)公布,旗下於全國中小企業股份轉讓系統上市的附屬原子高科研發的一類創新藥「氟[18F]司他明注射液」通過審查,獲得國家藥監局(NMPA)核准簽發的《藥物臨床試驗批准通知書》,同意按照提交的方案開展臨床試驗。 氟[18F]司他明注射液最初由南韓FutureChem開發,用於前列腺癌診斷、分期和生化復發的檢查。2020年9月1日,原子高科與南韓FC簽署合作開發協議,獲得該產品在中國的開發、生產和市場銷售的獨家權利。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account